EXVASTAT
Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The new treatment has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers.
EXVASTAT
Industry:
Biotechnology Health Care Life Science Medical Pharmaceutical
Founded:
2016-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.exvastat.com
Total Employee:
1+
Status:
Active
Total Funding:
3.9 M USD
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail Google Apps For Business Cloudflare JS CDN JS Pexels Twitter CDN WordPress 5.5
Current Advisors List
Current Employees Featured
Founder
Investors List
Innovative Medicines Initiative
Innovative Medicines Initiative investment in Grant - Exvastat
Cambridge Innovation Capital
Cambridge Innovation Capital investment in Seed Round - Exvastat
Official Site Inspections
http://www.exvastat.com
- Host name: olympus-lon.cloudhosting.uk
- IP address: 185.199.220.69
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Exvastat"
Exvastat - Crunchbase Company Profile & Funding
Organization. Exvastat . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Exvastat is an innovative, preclinical-stage …See details»
About us - Exvastat
Exvastat Ltd have been supported by investment from Cambridge Innovation Capital, who invest in intellectual property rich companies from the University of Cambridge and the wider …See details»
Exvastat Company Profile 2024: Valuation, Funding & Investors
Exvastat General Information Description. Developer of respiratory distress drugs intended to help healthcare providers cure acute respiratory distress syndrome. The company's drugs can …See details»
EXVASTAT LTD Company Profile - Dun & Bradstreet
Exvastat ltd. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united kingdom / …See details»
Exvastat - Overview, News & Similar companies | ZoomInfo.com
May 14, 2020 Exvastat Ltd is a single asset biopharmaceutical company established in 2016 with investment from Cambridge Innovation Capital (CIC). The founders, Drs. David Cavalla …See details»
Exvastat Company Profile - Office Locations, Competitors ... - Craft
Exvastat has 5 employees across 2 locations and $3.89 m in total funding,. See insights on Exvastat including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Exvastat - Products, Competitors, Financials, Employees, …
May 22, 2020 Exvastat's innovation addresses the unmet medical need for an approved pharmacotherapy for ARDS, which is caused by conditions such as pneumonia, sepsis, and …See details»
Exvastat - Company Profile - Tracxn
Exvastat - Developer of repurposed drug for acute respiratory distress syndrome. Raised a total funding of $2.95M over 4 rounds from 8 investors. Valued at $41.4M. Exvastat has 126 …See details»
Further investment and three new appointments announced
Aug 6, 2021 Exvastat is a clinical stage company developing intravenous imatinib (Impentri™) as a first-in-class pharmacotherapy for all-cause ARDS and COVID-19 pneumonia to lower …See details»
Exvastat - LinkedIn
Exvastat is an innovative, preclinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug ...See details»
Exvastat - VentureRadar
Exvastat is an innovative, clinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a …See details»
Exvastat - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Exvastat . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... Exvastat has 1 board member or advisor, …See details»
Exvastat - Funding, Financials, Valuation & Investors - Crunchbase
Exvastat is an innovative, preclinical-stage pharmaceutical company. How much funding has this organization raised over time? ShowSee details»
Exvastat Home – Impentri
Impentri is the first specific drug treatment for acute respiratory distress syndrome (ARDS) Exvastat is an innovative, clinical-stage pharmaceutical company founded in 2016. The …See details»
Contact - Exvastat
[email protected]. Impacting countless lives by defeating ARDS from any cause. Nine Hills Rd, Cambridge. CB2 1GE, UK. [email protected]. supported by ©2021 Exvastat Ltd. …See details»
Impentri – Impentri_IMI2
The Consortium. The Impentri IMI2 consortium have been awarded a €3.6M grant by IMI, to develop an existing licensed drug, imatinib for the treatment of Acute Respiratory Distress …See details»
Appointment of Dr Julian Gilbert as Non-Executive Director
Cambridge, UK [26th April 2021]: Exvastat Limited is pleased to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Julian has more than 30 years of …See details»
Science - Exvastat
Using in vitro measures of endothelial permeability, Aman et al (2012) demonstrated that imatinib preserves endothelial barrier integrity during stimulation with inflammatory stimuli. The effect …See details»
News - Exvastat
Jun 21, 2021 Results published on Friday 18th June by Exvastat’s collaborator in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality …See details»